Selection of qualified investigators is an essential component of each clinical drug development program. A monitor executes the sponsor's regulatory responsibility to select qualified investigators. However, sponsors and monitors must decide, in a manner consistent with the regulations, what constitutes appropriate qualifications for investigators under a specific Investigational New Drug (IND) application. This paper summarizes information from regulations, guidelines, and other sources in order to help sponsors and monitors properly address this important issue for their clinical investigations
Title 21.Code of Federal Regulations. Part 312.3. Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
2.
Title 21. Code of Federal Regulations. Part 312.53 (c)(viii). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
3.
BartonBL. Regulatory audits of clinical investigations: an FDA perspective. Presented at the Annual Meeting of the Associates of Clinical Pharmacology; May 1990; Montreal, Quebec.
4.
Title 21.Code of Federal Regulations. Part 312.50. Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
5.
Title 21.Code of Federal Regulations. Part 312.53(d). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
6.
United States Food and Drug Administration.Guideline for the Monitoring of Clinical Investigations.Washington, D.C.: U.S. Government Printing Office; January 1988.
7.
Title 21.Code of Federal Regulations. Part 312.53(a). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
8.
Title 21. Code of Federal Regulations. Part 312.53(c)(2). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
9.
Food and Drug Administration.Obligations of sponsors and monitors of clinical investigations. Proposed establishment of regulations. Federal Register. September 27, 1977; 42 (No. 187):49612.
10.
United States Food and Drug Administration.General Considerations for the Clinical Evaluation of Drugs.Washington, DC: U.S. Government Printing Office; September 1977.
11.
Title 21.Code of Federal Regulations. Part 312.53(c)(vi)(a). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
12.
Title 21.Code of Federal Regulations. Part 312.53(c)(vi)(c). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
13.
United States Food and Drug Administration.Compliance Program Guidance Manual. Program 7348.811. Chapter 48. Bioresearch Monitoring — Human Drugs. Clinical Investigators. Part III, page 9. September 30, 1991.
14.
Title 21.Code of Federal Regulations. Part 312.62(b). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
15.
TurnerGLisookABDelmanDP. FDA's conduct, review, and evaluation of inspections of clinical investigators. Drug Inf J.1987;21: 117–125.
16.
Title 21.Code of Federal Regulations. Part 312.70. Disqualification of a clinical investigator. Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
17.
Title 21. Code of Federal Regulations. Part 16. Regulatory hearing before the Food and Drug Administration. Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
18.
LawrenceCS. FDA inspection of clinical research sponsors and investigators: Avoiding the pitfalls. Drug Inf J.1988;22: 207–223.
19.
DormerRA. Handling an investigator disqualification proceeding — the investigator's perspective. Food Drug Cosmetic Law Journal.1990;45: 717–722.
20.
LisookAB. FDA audits of clinical studies: Policy and procedures. J Clin Pharmacol.1990;30: 296–302.
21.
KelseyFO. The Bioresearch Monitoring Program. Food Drug Cosmetic Law Journal.1991;46: 59–63.
22.
LittleLS. The role of the HHS Office of Inspector General in the investigation of scientific misconduct. Food Drug Cosmetic Law Journal.1991;46: 65–69.
23.
Food and Drug Administration.Investigators ineligible to receive investigational new drugs. March 1991.
24.
Food and Drug Administration.Investigators agreeing to some restriction of investigational drug use. March 1991.
25.
Food and Drug Administration.Assurances for future investigational drug study performance accepted. March 1991.
26.
Title 21.Code of Federal Regulations. Part 312.120(c)(4). Washington, D.C.: U.S. Government Printing Office; April 1, 1990.
27.
CPMP Working Party on Efficacy of Medicinal Products.Good Clinical Practice for Trials on Medicinal Products in the European Community.Brussels: Commission of the European Communities, July 11, 1990.
28.
Practice guidelines for pharmacotherapy specialists.A position statement of the American College of Clinical Pharmacy. Pharmacotherapy.1990;10: 308–311.
